Brazilian study links postnatal rapid weight gain to elevated paediatric BMI
Rapid weight gain in early life is a well-documented risk factor for childhood obesity, as well as the onset of …
Post
-
-
New HBV vaccine guidance likely to increase infection among newborns
The US Advisory Committee on Immunization Practices (ACIP) has voted to recommend delaying the hepatitis B virus (HBV) vaccination administered …
-
Novartis reports positive data from VAYHIT2 trial for immune thrombocytopenia
Novartis has reported positive outcomes from the VAYHIT2 Phase III trial assessing ianalumab plus eltrombopag to treat patients with primary immune …
-
ASH 2025: potential new BCL2 inhibitor option for R/R CLL
At the 2025 American Society of Hematology (ASH) Congress, held on 5-9 December, results from a Phase II pivotal study …
-
Daiichi Sankyo announces first patient dosed in Phase III trial of Enhertu
Daiichi Sankyo has announced the dosing of first patient in the DESTINY-Ovarian01 Phase III trial’s randomisation phase, assessing Enhertu (trastuzumab …
-
Dyne to seek accelerated approval of DMD drug on Phase I/II data
Dyne Therapeutics is seeking US accelerated approval of its Duchenne muscular dystrophy (DMD) drug after it met its endpoints in …
-
Utilising real-world data to overcome challenges in rare disease research
Innovative approaches like synthetic control arms based on real-world data may help overcome the unique challenges faced in clinical trials …
-
ASH 2025: MSD’s B-ALL drug shows potential, but all patients experience AEs
MSD said its newly acquired T-cell engager has demonstrated acceptable tolerability and safety in relapsed or refractory B-cell acute lymphoblastic …
-
ASH 2025: Arcellx and Gilead’s Anito-cel challenges CAR-T market in R/R MM
At the American Society of Hematology (ASH) Annual Meeting 2025, held in Orlando, Florida and online from 7 to 10 …
-
Kallyope’s migraine drug advances to pivotal trial
Kallyope is advancing its lead migraine drug to pivotal trials after it has shown to be competitive with marketed therapies …
-
ASH 2025: Cullinan’s T-cell engager boasts potential across p53 AML subset
Cullinan Therapeutics’ T-cell engager, CLN-049, has been proven tolerable and safe in an early-stage study in relapsed or refractory acute …
-
Clinical Trials Arena Excellence Awards 2025: Flex Databases
Flex Databases won the Innovation, Product Launches, and Business Expansion awards in the 2025 Clinical Trials Arena Excellence Awards for …
-
Structure Therapeutics announces positive results from aleniglipron trial
Structure Therapeutics has reported positive topline results from the ACCESS clinical programme for its investigational oral glucagon-like-peptide-1 (GLP-1) receptor agonist, …
-
Citryll doses first patient in Citylights trial for hidradenitis suppurativa
Citryll has dosed the first patient in the Phase IIa Citylights clinical trial of the monoclonal antibody, CIT-013, for moderate-to-severe …
-
From Email Chaos to Ethical Intelligence: WCG’s CEO on the New Era of Review Management
WCG CEO Sam Srivastava explains how the company’s award‑winning ClinSphere® eReview Manager is reinventing ethics review as an AI‑enabled, interoperable, …
